Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, representing a backend/frontend platform update rather than content changes.SummaryDifference0.1%

- Check21 days agoChange DetectedThe study's list of identifiers now includes '2016 ( U.S. NIH Grant/Contract )', adding NIH grant attribution to the record.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedA new revision label v3.6.5 was added to the page and the previous label v3.6.4 was removed, signaling a small platform build update.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page revision metadata was updated from v3.6.3 to v3.6.4, signaling a minor update to the record's metadata; no changes to the study content are indicated.SummaryDifference0.0%

- Check71 days agoChange DetectedThe footer revision label changed from v3.6.2 to v3.6.3, indicating a minor site update. No core content or study data on the page is affected by this change.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2 on the page, signaling a version update of the page rendering. This appears to be a backend/content-management-system update rather than a modification to the study data or user-facing content.SummaryDifference0.0%

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.